Advertisement
U.S. markets open in 4 hours 45 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
40.37-0.49 (-1.20%)
At close: 04:00PM EDT
40.37 0.00 (0.00%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close40.86
Open40.93
Bid40.29 x 800
Ask41.15 x 800
Day's Range40.32 - 40.96
52 Week Range29.85 - 45.00
Volume922,123
Avg. Volume1,412,645
Market Cap5.129B
Beta (5Y Monthly)1.25
PE Ratio (TTM)19.22
EPS (TTM)2.10
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
61% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HALO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Halozyme Therapeutics, Inc.
    HALO: Raising target price to $44.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $44.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GuruFocus.com

    Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...

    Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment, has reported an insider sell according to a recent SEC filing.

  • Insider Monkey

    Should You Hold Halozyme Therapeutics (HALO)?

    Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The portfolio had a positive absolute return in Q4 but underperformed the Russell 2000 Growth Index due to security selection, particularly in the healthcare and information technology sectors. In the […]

  • PR Newswire

    Halozyme to Participate in Upcoming Investor Conferences

    Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences: